Alvotech
Manufacturing · Iceland · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
15-19 Saemundargata, Reykjavik, Capital ...Phone Number
+354 4224500Website
www.alvotech.comRevenue
$586.3 MillionStock Symbol
ALVOIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patientsRead more
Alvotech Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alvotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Alvotech launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Alvotech has new funding data
Congratulate Masked Content for being promoted to Masked Content at Alvotech
Earning: See what the market has to say on Alvotech recently announced quarterly report
Check out if Alvotech is spiking on competitors!
Alvotech, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Alvotech had a recent Job posting/layoffs
Check if Alvotech has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Alvotech
Find more new buyers
Company Profile Activity
Activity Insights
Alvotech is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alvotech is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alvotech.
Alvotech financials insights
Gather financial insights about Alvotech, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Other Financing Round
$300M
2021
Share Placement
$35M
2022
Multiple Rounds
$136M
2023
Debt
$100M
2026
Debt
$117.2M
Alvotech Tech Stack
A closer look at the technologies used by Alvotech
Most Recent Scoops
Open Position
Person-Based
Compliance, Pharmaceuticals
Person-Based
Finance, Investor Relations
Person-Based
Earnings, Finance, Investor Relations
Person-Based
Clinical Operations
Alvotech News & Media
Alvotech (ALVO): 10 Penny Stocks With Explosive Growth Potential
Alvotech (NASDAQ:ALVO) is one of the penny stocks with explosive growth potential. On June 18, Alvotech closed its underwritten public offering of 26,066,667 ordinary shares at $3.75 per share, raising ~$98 million in gross proceeds. This figure includes the full exercise of the underwriters’ option to purchase additional shares. The offering is complemented by a […]Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
REYKJAVIK, ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing on June 17, 2026 of its previously announced underwritten public offering (the “Offering”) of 26,066,667 of its ordinary shares at an offering price of $3.75 per share, which includes 3,400,000 ordinary shares issued pursuant to the exercise iAlvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
REYKJAVIK, ICELAND (June 16, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 22,666,667 of its ordinary shares at an offering price of $3.75 per share. All ordinary shares to be sold in the Offering will be offered by Alvotech. The Offering is
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alvotech
Sign Up For FreeTo access detailed company insights
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditio... Read More
